Eczema drug SHR-1819 put to the test in extended trial
NCT ID NCT06012812
First seen Mar 05, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study looked at the long-term safety and effectiveness of the drug SHR-1819 in 79 adults with moderate to severe atopic dermatitis (eczema) who had already taken part in earlier studies of the same drug. Researchers monitored side effects and how well the drug controlled the skin condition over time. The goal was to see if continued treatment remains safe and helpful for managing eczema.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital,Fudan University
Shanghai, Shanghai Municipality, 200040, China
Conditions
Explore the condition pages connected to this study.